



European Patent to be Granted for Cholesterol-Lowering Drug

- The European Patent Office has issued a Notice of Intention to grant Nyrada’s patent application for novel compounds inhibiting PCSK9. The patent will provide protection for Nyrada’s PCSK9 inhibitor technology until 2038.
- Nyrada’s oral PCSK9 inhibitor creates the potential for a next generation alternative to expensive and inconvenient PCSK9 injectable drugs.
- Granting of the European patent will further strengthen the Company’s intellectual property portfolio, adding to the US patent already granted in July 2021.

Sydney, 17 May 2022: Nyrada Inc (ASX: NYR) (“Nyrada” or “the Company”) a preclinical stage, drug development company specialising in novel small molecule drugs to treat cardiovascular and neurological diseases, is pleased to announce the European Patent Office (EPO) has issued a Notice of Intention to grant the Company’s patent application number EP18768188.7.

The application covers novel compounds developed by Nyrada that act as inhibitors of PCSK9 to enable a reduction in LDL (bad) cholesterol levels.

Importance of LDL Cholesterol to Health and the Role of PCSK9

When the body has too much LDL cholesterol, it can accumulate on artery walls, restricting blood flow which can lead to heart attack and stroke. LDL cholesterol is cleared from circulation by binding to LDL receptors (LDLR) on the surface of liver cells. PCSK9 is a naturally produced protein that plays a counter role in this regulation process. It does this by degrading the LDLR, lowering the number of receptors available to remove LDL cholesterol. This leads to increased levels of LDL cholesterol in the bloodstream. Inhibition of PCSK9 causes a beneficial increase in LDLR on the surface of cells, improving the body’s ability to clear LDL cholesterol from the bloodstream.

The patent is expected to be granted by the EPO once the final administrative steps have been completed. The composition of matter patent will provide protection for Nyrada’s intellectual property (IP) relating to its PCSK9 inhibitor technology until 16 March 2038. The granting of this patent will strengthen the Company’s ability to pursue commercial negotiations with pharmaceutical companies.

The new European patent will build on the corresponding patent granted by the United States Patent and Trademark Office (USPTO) announced by the Company in July 2021. Notably, these patents are entirely owned by Nyrada and the Company’s IP assignment is free of royalties or other incumbrances.

Commenting on the impending granting of the patent, Nyrada CEO, James Bonnar said: “Nyrada is pursuing an active IP strategy for its Cholesterol-Lowering program and making timely progress. As we get closer to clinical testing of our PCSK9 inhibitor technology in healthy volunteers, it is prudent to have our IP protection in place to support our business development position. I am delighted that Nyrada’s PCSK9 inhibitor technology will soon be protected in two substantial markets, the US and Europe.

“Although the primary objective of the Phase I study is to evaluate our drug candidate for safety and tolerability, we will also assess blood cholesterol levels as a secondary end point to determine the drug’s efficacy,” Mr. Bonnar added.

About Nyrada Inc

Nyrada is a preclinical stage, drug discovery, and development company, specialising in novel small molecule drugs to treat cardiovascular and neurological diseases. The Company has two main programs, each targeting market sectors of significant size and considerable unmet clinical need. These are a cholesterol-lowering drug and a drug to treat brain injury, specifically traumatic brain injury and stroke. Nyrada Inc. ARBN 625 401 818 is a company incorporated in the state of Delaware, US, and the liability of its stockholders is limited.

www.nyrada.com

Authorised by Mr. John Moore, Non-Executive Chairman, on behalf of the Board.

Investor & Corporate Enquiries:

Laura Vize, Investor Relations Manager
T: 02 9498 3390
E: info@nyrada.com

Company Secretary:

David Franks
T: 02 8072 1400
E: David.Franks@automicgroup.com.au

Media Enquiries:

Catherine Strong
Citadel-MAGNUS
T: 02 8234 0111
E: cstrong@citadelmagnus.com

Forward-Looking Statements

This announcement may contain forward-looking statements. You can identify these statements by the fact they use words such as “aim”, “anticipate”, “assume”, “believe”, “continue”, “could”, “estimate”, “expect”, “intend”, “may”, “plan”, “predict”, “project”, “plan”, “should”, “target”, “will” or “would” or the negative of such terms or other similar expressions. Forward-looking statements are based on estimates, projections, and assumptions made by Nyrada about circumstances and events that have not yet taken place. Although Nyrada believes the forward-looking statements to be reasonable, they are not certain. Forward-looking statements involve known and unknown risks, uncertainties, and other factors that are in some cases beyond the Company’s control (including but not limited to the COVID-19 pandemic) that could cause the actual results, performance, or achievements to differ materially from those expressed or implied by the forward-looking statement.